Navigation Links
Study identifies causes of bone loss in breast cancer survivors
Date:11/19/2008

MAYWOOD -- Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.

But a new study has found that cancer drugs aren't the only culprits. Among 64 breast cancer patients referred to a bone health clinic, 78 percent had at least one other cause of bone loss, including vitamin D deficiency, excessive calcium excretion in urine and an overactive parathyroid gland.

"Doctors evaluating breast cancer patients for possible bone loss should look further than cancer drugs," said Dr. Pauline Camacho, lead author of the study in the Journal of Clinical Oncology. Camacho is an associate professor in the department of medicine, division of endocrinology and metabolism, Loyola University Chicago Stritch School of Medicine.

A co-author of the study, Dr. Kathy Albain, said breast cancer survivors "are just like the normal population as they age in that bone loss can be due to many treatable causes." Albain is a professor in the Department of Medicine, division of hematology/oncology at Stritch.

Previous studies have found that chemotherapy drugs can cause bone loss. Studies also have found that a class of breast cancer drugs called aromatase inhibitors can decrease bone mineral density and increase the risk of fractures in postmenopausal women. Aromatase inhibitors decrease the body's production of estrogen. While estrogen feeds cancer, it also protects against osteoporosis. Aromatase inhibitors include letrozole (trade name, Femara), anastrazole (Arimidex) and exemestane (Aromasin).

Researchers reviewed charts of 238 consecutive postmenopausal patients who had osteoporosis or osteopenia and were referred to the Loyola's Osteoporosis and Metabolic Bone Disease Center from 2000 to 2006. (Osteopenia is lower than normal bone mineral density, but not low enough to be classified as osteoporosis.) The patients included 64 women with breast cancer referred from Loyola's Cardinal Bernardin Cancer Center and 174 patients without breast cancer referred from primary care physicians.

Thirty eight percent of the breast cancer patients had vitamin D deficiency, compared with 51 percent of the non breast cancer patients. Another cause of osteoporosis, excessive calcium excretion in urine, was found in 16 percent of cancer patients and 8 percent of noncancer patients. And in 5 percent of patients, the parathyroid gland was overactive, producing a hormone that causes bone to lose calcium.

Vitamin D deficiency can be treated with prescription doses of vitamin D supplements. Excessive calcium excretion can be treated with a "water pill" that's also used to treat high blood pressure, Camacho said. There are various treatments for parathyroid gland disorder, depending on its cause.

In certain breast cancer patients, bone loss from cancer drugs can be treated with osteoporosis drugs such as alendronate sodium (Fosamax) and ibandronate sodium (Boniva), Camacho said.

Albain refers all her breast cancer patients for a comprehensive bone health evaluation when osteopenia or osteoporosis is discovered. "Just prescribing a medication for osteoporosis may not be enough for many of our patients," Albain said. "They deserve a thorough workup."

Patient Rosaleen O'Connor, 71, of Elmhurst, Il., learned she had osteoporosis while being treated by Albain for breast cancer. Albain referred O'Connor to Camacho, who prescribed calcium supplements, prescription vitamin D and the osteoporosis drug Boniva. Three years after O'Connor was diagnosed, her Stage 3 cancer is in remission, and she has suffered no bone fractures.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
2. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
3. Rutgers researchers study cites media violence as critical risk factor for aggression
4. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
5. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
6. New Study Finds CO2 Ablative Fractional Resurfacing Safe And Effective For Deep Acne Scarring
7. Study investigates Gore-tex-type device to stop strokes and mini-strokes
8. The smart way to study
9. Case Western Reserve University study examines working couples retirement patterns
10. Surgical study highlights pros and cons of gastric bypass surgery for severe obesity
11. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... 25, 2017 , ... Bellus Medical, a leader in medical ... new class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream ... of aging, and minimize the appearance of pores – all with minimal downtime ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology: